Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA1 | P00915 | 2/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.46 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.46 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.43 |
| ▸ | CA2 | P00918 | 1/20 | 0.42 |
| ▸ | ACHE | P22303 | 1/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.37 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.35 |
| ▸ | GABRP | O00591 | 2/20 | 0.33 |
| ▸ | GABRD | O14764 | 2/20 | 0.33 |
| ▸ | GABRA1 | P14867 | 2/20 | 0.33 |
| ▸ | GABRB1 | P18505 | 2/20 | 0.33 |
| ▸ | GABRG2 | P18507 | 2/20 | 0.33 |
| ▸ | GABRB3 | P28472 | 2/20 | 0.33 |
| ▸ | GABRA5 | P31644 | 2/20 | 0.33 |
| ▸ | GABRA3 | P34903 | 2/20 | 0.33 |
| ▸ | GABRA2 | P47869 | 2/20 | 0.33 |
| ▸ | GABRB2 | P47870 | 2/20 | 0.33 |
| ▸ | GABRA4 | P48169 | 2/20 | 0.33 |
| ▸ | GABRE | P78334 | 2/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18161881 | 0.95 | CA1 (0.48) | CA1ALDH1A1TDP1CYP2C19CA2 | |
| SCHEMBL16791086 | 0.85 | CA1 (0.44) | CA1ALDH1A1TDP1CYP2C19CA2 | |
| SCHEMBL110531 | 0.85 | CA1 (0.60) | CA1ALDH1A1TDP1CA2TRPA1 | |
| SCHEMBL106845 | 0.84 | CA1 (0.42) | CA1ALDH1A1TDP1CYP2C19CA2 | |
| SCHEMBL15345276 | 0.84 | ALDH1A1 (0.46) | CA1ALDH1A1TDP1CYP2C19CA2 | |
| SCHEMBL14350722 | 0.82 | CA1 (0.57) | CA1ALDH1A1TDP1CA2TRPA1 | |
| SCHEMBL13817695 | 0.82 | ALDH1A1 (0.40) | CA1ALDH1A1TDP1CYP2C19CA2 | |
| SCHEMBL6064551 | 0.82 | CA1 (0.46) | CA1ALDH1A1TDP1CYP2C19CA2 | |
| SCHEMBL30643272 | 0.82 | ALDH1A1 (0.40) | CA1ALDH1A1TDP1CYP2C19CA2 | |
| SCHEMBL30122637 | 0.82 | GABRP (0.50) | CA1ALDH1A1TDP1CYP2C19GABRP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 172 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2463374-A2 | Isolated alcohol dehydrogenase enzymes and uses thereof | Bio Architecture Lab, Inc. (US) | 2012-06-13 | — | — | EP | claimed |
| EP-2195440-A2 | BIOFUEL PRODUCTION | Bio Architecture Lab, Inc. (US) | 2010-06-16 | — | — | EP | claimed |
| US-20090155873-A1 | BIOFUEL PRODUCTION | BIO ARCHITECTURE LAB, INC. (US) | 2009-06-18 | — | — | US | claimed |
| US-20090139134-A1 | BIOFUEL PRODUCTION | BIO ARCHITECTURE LAB, INC. (US) | 2009-06-04 | — | — | US | claimed |
| WO-2009046375-A2 | BIOFUEL PRODUCTION | BIO ARCHITECTURE LAB, INC. (US) | 2009-04-09 | — | — | WO | claimed |
| WO-2009046370-A2 | BIOFUEL PRODUCTION | BIO ARCHITECTURE LAB, INC. (US) | 2009-04-09 | — | — | WO | claimed |
| EP-3230463-B2 | RAPID PRETREATMENT | APALTA PATENTS OUE (EE) | 2025-07-16 | — | — | EP | disclosed |
| US-20240425893-A1 | RAPID PRETREATMENT | Apalta Patents OÜ (EE) | 2024-12-26 | — | — | US | disclosed |
| US-12054761-B2 | Rapid pretreatment | Apalta Patents OÜ (EE) | 2024-08-06 | — | — | US | disclosed |
| US-20240066133-A1 | THERAPEUTIC AGENTS AND CONJUGATES THEREOF | AJ SCIENCES (YIXING) CO., LTD (CN) | 2024-02-29 | — | — | US | disclosed |
| US-11834463-B2 | High affinity macrocyclic FKB51-inhibitors for treatment of psychiatric disorders | Technische Universität Darmstadt (DE) | 2023-12-05 | — | — | US | disclosed |
| US-11821047-B2 | High pressure zone formation for pretreatment | Apalta Patent OÜ (EE) | 2023-11-21 | — | — | US | disclosed |
| US-11802132-B2 | Small molecules for inducing selective protein degradation and uses thereof | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2023-10-31 | — | — | US | disclosed |
| US-6447557-B1 | HYDROCARBON OXYENATE WHICH IS SATURATED, ALIPHATIC MONOHYDRIC ALCOHOL, MONO- OR POLY-KETONE OR KETO-MONOHYDRIC ALIPHATIC ALCOHOL; ULTRA-LOW SULPHUR FUEL WITH REDUCED PARTICULATE EMISSIONS OVER A BROAD RANGE OF VEHICLES AND DRIVING CYCLES | EXXONMOBIL RESEARCH AND ENGINEERING COMPANY | 2002-09-10 | — | — | US | disclosed |
| US-20020108299-A1 | Diesel fuel composition | EXXONMOBIL RESEARCH & ENGINEERING COMPANY | 2002-08-15 | — | — | US | disclosed |
| US-20020104256-A1 | Diesel fuel composition | EXXONMOBIL RESEARCH & ENGINEERING COMPANY | 2002-08-08 | — | — | US | disclosed |
| US-20020000063-A1 | Diesel fuel composition | EXXONMOBIL RESEARCH & ENGINEERING COMPANY | 2002-01-03 | — | — | US | disclosed |
| WO-2001046349-A1 | DIESEL FUEL COMPOSITION | EXXONMOBIL RESEARCH AND ENGINEERING COMPANY (US) | 2001-06-28 | — | — | WO | disclosed |
| WO-2001046348-A1 | DIESEL FUEL COMPOSITION | EXXONMOBIL RESEARCH AND ENGINEERING COMPANY (US) | 2001-06-28 | — | — | WO | disclosed |
| WO-2001046346-A1 | DIESEL FUEL COMPOSITION | EXXONMOBIL RESEARCH ENGINEERING COMPANY (US) | 2001-06-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11834463-B2 | High affinity macrocyclic FKB51-inhibitors for treatment of psychiatric disorders | FKBP1B, FKBP5, FKBP1A | CA1 4776/4885ALDH1A1 4075/4885TDP1 3893/4885 |
| US-20090139134-A1 | BIOFUEL PRODUCTION | MGAM, DCXR, MANBA | CA1 2232/4885ALDH1A1 753/4885TDP1 2746/4885 |
| US-11802132-B2 | Small molecules for inducing selective protein degradation and uses thereof | BAZ2A, BRD3, BRPF3 | CA1 4565/4885ALDH1A1 4164/4885TDP1 3208/4885 |
| US-20240066133-A1 | THERAPEUTIC AGENTS AND CONJUGATES THEREOF | TLR9, STING1, TLR3 | CA1 3710/4885ALDH1A1 4469/4885TDP1 218/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.